Austin-based MDisrupt, an AI-powered marketplace for healthcare technology, has secured a $1 million milestone-based investment from American Heart Association (AHA) Ventures.
The newly established venture firm from the AHA leads AHA’s investments and is designed to support groundbreaking innovations that align with the organization’s mission.
In tandem with this funding, MDisrupt and the AHA have entered into a service agreement to co-develop a platform to connect healthcare experts with innovators. This expansion will leverage the AHA’s vast network of clinicians, scientists, and business professionals. By integrating these resources into MDisrupt’s marketplace, the partnership aims to bridge the gap between innovation and clinical expertise.
MDisrupt, founded by Ruby Gadelrab, offers an AI-powered matchmaking platform that pairs healthcare and medtech companies with industry experts with over a decade of experience. This setup allows companies to access expert guidance in building clinically sound, impactful products. Gadelrab said in a news release, “We take care of all the contracting, liability insurance, and logistics, so clinicians and healthcare experts can focus on advising rather than the administrative tasks of industry work.”
This new collaboration with AHA Ventures will bring AHA members’ expertise to MDisrupt’s platform. Lisa Suennen, managing partner of AHA Ventures, explained, “People are looking for the expertise our members have because they want to apply the best evidence and science to their healthcare innovations. MDisrupt’s commitment to scientifically driven, evidence-based matchmaking aligns with our goals.”
Suennen noted that the AHA’s investment structure reflects their commitment to ensuring the platform’s development, explaining, “We provided three-quarters of the funding upfront, with the remaining quarter dependent on the successful beta launch of the co-developed product.” Set for a beta release in the latter half of 2025, the platform aims to facilitate referrals to experts, enabling innovators to apply science-backed insights throughout their development.
For MDisrupt, this partnership represents an opportunity to amplify the role of expert input in health tech. “Our mission is to help the most impactful healthcare products reach the market faster, with the right regulatory, clinical, and operational insights to make them truly viable,” Gadelrab said.
As MDisrupt and AHA Ventures bring this co-developed platform to life, both parties anticipate a significant impact on the quality and clinical relevance of next-generation healthcare and medtech solutions. Suennen concluded, “Our hope is for MDisrupt’s growth and success to bring more credibility and partners to the table, further elevating the standards for health technology.”